Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections

45th Interscience Conference on Antimicrobial Agents and Chemotherapy -- DEC 16-19, 2005 -- Washington, DCWOS: 000243742600010PubMed ID: 17189097Fosfomycin tromethamine (FT) is effective in vitro in extended spectrum beta-lactamase (ESBL)-producing Escherichia coli strains. The aim of this study was to evaluate the effect of FT in the treatment of ESBL-producing E. coli-related lower urinary tract infection. All patients were aged > 18; had dysuria or problems with frequency or urgency in passing urine; had > 20leukocytes/mm(3) in urine sediment and an ESBL-producing E. coli urine culture (> 10(5) cfu/mm(3)); no leukocytosis or fever; and were treated with FT between September 2004 and July 2006 in our outpatient clinic and hospital. ESBL detection was performed by double disk synergy tests. All patients had received FT (3 g x 1 every other night, three times) and had a control urine culture taken 7 to 9 days after this therapy. Clinical success was defined as resolution of symptoms on the control visit; microbiological success was defined as a sterile control urine culture. In all, 52 patients (aged 55.0 +/- 18.3, range 19-85; 25 males, 27 females) were included in the study. Overall clinical and microbiological success was 94.3% (49/52) and 78.5% (41/52), respectively. Although it is not a randomized controlled study, these data show that FIF may be a suitable, effective and cheap alternative in the treatment of ESBL-producing E. coli-related lower urinary tract infection. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved